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Interleukin-lO Inhibits Tumor Metastasis Through an NK 
Cell-dependent Mechanism 
By L.M. Zheng,* D.M. Ojcius,~ E Garaud, C. Roth,~ E. Maxwell,* 
Z. Li,* H. 1Kong,* J. Chen,* X.Y. Wang,* J.J. Catino,* and I. King* 
From *The Tumor Biology Department, Schering-Plough Research Institute, Kenilworth, New Jersey 
07033; and r de Biologie des Interactions Cellulaires and ~Unit~ de Biologie Mol~culaire du 
Gdne, Institut Pasteur, Paris, France 
Summary 
Interleukin-10 (IL-10) is a recently described pteiotropic ytokine secreted mainly by type 2 
helper T cells. Previous studies have shown that IL-t0 suppresses cytokine expression by natu- 
ral killer (NK) and type 1 T cells, thus down-regulating cell-mediated immunity and stimulat- 
ing humoral responses. We here report that injected IL-t0 protein is an efficient inhibitor of  
tumor metastasis in experimental (B16-F10) and spontaneous (M27 and Lox human mela- 
noma) metastasis models in vivo at doses that do not have toxic effects on normal or cancer 
cells. Histological characterization after IL-10 treatment confirmed the absence of CD8 + and 
CD4 + T cells and macrophages at the sites of  tumor growth, but abundant NK cells were lo- 
calized at these sites. This unexpected finding was confirmed by showing that IL-10 inhibits 
most B16-F10 and Lox metastases in mice deficient in T or B cells (SCID and nu/nu mice), 
but not in those deficient in NK cells (beige mice or NK cell--depleted mice). However, IL-t0 
downregulation of  pro-inflammatory c tokine production and/or recruitment of  additional ef- 
f~ctor cells may also be involved in the anti-tumor effect at higher local concentrations of IL-t0, 
since transfected B16 tumor cells expressing high amounts o f  lL-10 were rejected by normal, 
nu/nu, or SCID mice at the primary tumor stage, and there was still a 33% inhibition of  tumor 
metastasis n beige mice. 
A number of  cytokines have been used with variable success in attempts to control tumor growth and me- 
tastasis (1-8). Many of these cytokines, such as IL-2, IFN~/, 
TNFo~, and GM-CSF, also have direct toxic or stimulatory 
effects on the tumor cells, and may in some cases lead to 
malignancy of  otherwise normal cells (4, 9), thus compli- 
cating their clinical usefulness. We have therefore screened 
a number ofcytokines for their ability to inhibit tumor me- 
tastases, and found that one of  them, IL-10, is an efficient 
inhibitor of  tumor metastasis n vivo at doses that do not 
have a direct effect on normal or cancer cells. IL-10 acts on 
different cell types, stimulating differentiation of  B cells 
into antibody-secreting cells, and inhibiting the capacity of  
monocytes/macrophages to present antigens (10-12). In 
addition, IL-10 exerts an indirect effect on the immune 
system, by inhibiting the secretion of  proinflammatory c - 
tokines (IL-1, IL-6, IL-8, GM-CSF, and TNFc~) from type 
1 helper T cells, monocytes/macrophages, and polymor- 
phonuclear Ieukocytes, and by inhibiting the secretion of  
IFN~/by NK cells (12-15). Recent studies have shown that 
IL-IO downregulates cell-mediated responses and favors 
the humoral arm of immunity by decreasing production of  
cytokines involved in cell-mediated responses (12), and 
that IL-10 increases the susceptibility to bacterial and para- 
sitic infections (16, 17). We therefore also investigated the 
mechanism by which IL-10 inhibits tumor metastasis. We 
find that NK cells are the main effector cells recruited at 
the nontoxic concentrations of  IL-10 used here, although 
other effector cells and/or mechanisms may also be in- 
volved at higher IL-10 concentrations. 
Materials and Methods 
Tumor Cells and Experimental Animals. For all the experi- 
ments described here, 6--8-wk-old female C57/BL6 and BALB/C 
mice were purchased from Charles River Labs. (Wilmington, 
MA). The B16-F10 murine melanoma was provided by Dr. I. 
Fidler and M27 murine lung carcinoma by Dr. P. Brodt. Human 
IL-10 (hlL-10) was obtained from Schering-Plough Corp. (Union, 
NJ), and its specific activity was 3.1 • 107 U/rag. Athymic nu/ 
nu mice, beige mice, and SCID mice were from Harlen Spraque 
Dawley. 
Tumor Measurements. Experimental lung metastases were ob- 
tained after intravenous injection of B16-F10 murine melanoma 
cells in C57/BL6 (H-2 b) mice, athymic nu/nu mice, and beige 
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mice. Spontaneous lung metastases were obtained by subcutane- 
ous injection of M27 Lewis lung carcinoma cells in C57/BL6 
mice, and Lox human melanoma cells in SCID mice. hlL-10 (up 
to 150 ~g/kg) was injected intraperitoneaUy. Tumor diameters 
were measured with calipers, groups of 10 mice were used for 
each condition, and each experiment was repeated atleast wice. 
The number of lung metastases was determined in double-blind 
measurements. Statistical analysis was performed using the non- 
parametric one tailed Mann-Whitney U test. 
For experiments with mice depleted of NK ceils, mice were 
injected intravenously with 100 I~g of a mAb against NKI.1 
(PharMingen, San Diego, CA) on day -1 ,  day 0 and day 1 after 
injection of tumor cells (1 • 105 ceils/animal). Animals received 
IgG2a isotype antibodies as a control for the specificity of the 
anti-NKl.1 mAb. Treatment with hlL-10 started on day 0, day 1 
and day 2 after tumor cell injection. Lung metastases were 
counted on day 14. 
For experiments with tumor ceils transfected with the IL-10 
gene, cells were co-transfected with pSV2 neo and a plasmid con- 
taining the human IL-10 gene. G418-resistant colonies were iso- 
lated, and IL-10 protein secretion was measured by ELISA. 
Immunohistological Analysis. Sections for immunohistochemis- 
try were prepared and labeled with antibodies as previously de- 
scribed (18). Monoclonal antibodies against CD3 (500 A2), CD4 
(L3T4), CD8 (Lyt2), CD90 (Thy-1), NK-I.1, and Mac-3 were 
from PharMingen; against LGL-I (4Dll), from Dr. L. Mason; 
against asialo-GM~, from Wako Chemicals US (Richmond, VA); 
against Mac-1 and Mac-2, from Boehringer Mannheim Corp. 
(Indianapolis, IN); and mAb BMA-BM8 against resident issue 
macrophages, from Accurate Chemical & Scientific Corp. (West- 
bury, NY) 
Resu l ts  
Direct Effect of lL-IO on Tumor Cells In Vitro and In Vivo. 
In preliminary experiments, it was established that hlL-10 
does not have direct toxic or stimulatory effects on the tu- 
mor cells when tumor cell ines are treated in vitro with up 
to 1 btg/ml (corresponding to 10 s U/m/) of hlL-10 (not 
shown). Likewise, no discernible toxic effect was observed 
in mice when hlL-10 doses as high as 700 txg/kg were 
used, although primary tumor growth in animals was par- 
tially affected by treatment with higher concentrations of
hlL-10. Thus, murine monocytic (nu/nu or BALB/c 
mice) and OVCAR 5 human ovarian (nu/nu mice) pri- 
mary tumors were not affected by hlL-10 doses from 5 to 
250 l*g/kg daily, while higher doses inhibited slightly the 
growth of B16-F10 murine melanoma (nu/nu or C57/ 
BL6) and U937 (nu/nu) tumors (<~40% inhibition) (not 
shown). 
Effect of lL- I0 on Tumor Metastasis. In order to measure 
the effects of IL-10 on tumor metastasis in animals, hlL-10 
(up to 150 I~g/kg) was injected intraperitoneally fo owing 
various doses and schedules. Daily injection of hlL-10 re- 
duced significantly the number of lung metastases in both 
spontaneous and experimental models. The inhibition was 
dose-dependent, as shown in Fig. 1 for the experimental 
metastatic model (B16 cells) and the spontaneous metastatic 
model (M27 cells). Inhibition in C57/BL6 mice reached 
68.4% for B16-F10 tumors at 150 Ixg/kg, and 90.2% for 
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Figure 1. Inhibitory effect of hlL-10 on lung metastasis in C57/BL6 
mice of (A) B16 and (B) M27 tumors. Mice were injected in ravenously 
with 1 • 10 s B16 or subcutaneously with 2 • l0 s M27 cells on day 0, 
and hlL-10 treatment was initiated on day 1. Mice treated with hlL-10 
exhibited a 64.3% (P = 0.008) inhibition of metastasis at a dose of 10 p.g/kg 
IL-10, 58.8% (P = 0.01) at a dose of100 I~g/kg, and 68.4% (P = 0.002) 
at a dose ofI50 txg/kg for B16 tumors on day 9 after injection; and mice 
treated with 100 b~g/kg and 150 ~g/kg ofhlL-10 exhibited a 90.2% (P = 
0.003) and 80.4% (P = 0.048) inhibition of metastasis, respectively, for
M27 tumors on day 28, compared with the vehicle control groups (Veh). 
M27 tumors. Moreover, treatment does not need to begin 
at the same time as tumor implantation, since administra- 
tion ofh lL-10 for 3 d starting on the day after tumor cell 
inoculation results in a 66.1% inhibition of metastases of 
B 16 tumors (not shown). 
It has recently been shown that Chinese hamster ovary 
(19) or mammary adenocarcinoma cells transfected (20) 
with the IL-10 gene were less effective at establishing pri- 
mary tumors than untransfected cells. We therefore in- 
jected animals with B16-F10 tumor cells transfected with 
the gene coding for hlL-10 and secreting different amounts 
of hlL-10 to ascertain whether they displayed metastatic 
behavior. Some of the transfected tumor cells were not able 
to form solid tumors, and metastases were also effectively 
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Figure 2. Effects ofIL-10-gene transfected B16 tumors. (A) Inhibition 
of solid tumor growth ( umor size given as a function of time, in days). 
C57/BL6 mice were injected subcutaneously with 1 • 106 IL-10-trans- 
fected B16 clones secreting varying amounts of IL-10. Compared to the 
B16 cell line transfected with the plasmid control (B16-Vector), there was 
100% inhibition of primary tumor growth for B16 clone #IA, and over 
50% inhibition for clones #4and #9. Groups of ten mice were used for 
each clone, and each experiment was repeated atleast wice. (/3) Inhibi- 
tion orB16 metastases. Mice were injected intravenously with 1 • l0 s 
B16 cells transfected with the IL-10 gene. Mice were killed on day 9, and 
the lung metastases were counted. Lung metastasis inhibition for each 
clone was as follows: #1A, 100%; #4, 86.4%; #5, 89.6%; #8, 94.7%; #9, 
85.8%; #17, 92%. IL-10 secretion (in g/million cells/48 h) for each 
clone was as follows: clone #1A, 400-500; #4,11.8; #5, 3.5; #8, 6.3; #9, 
5.9; #17, 1.4. 
day 28 after subcutaneous injection of  2 • 105 transfected 
cells was 82 and 84.3%, respectively (not shown). 
Identification of Effector Cells Involved in Metastasis Inhibi- 
lion. Previous studies have demonstrated that macrophages 
(2, 3, 21), helper T cells (22, 23), cytotoxic T ceils (1, 7, 8), 
and NK cells (7, 24) may contribute to the rejection of  tu- 
mors treated with different cytokines or transfected with 
genes coding for those cytokines. In order to determine the 
nature of  the effector cells responsible for IL-10-mediated 
inhibition of  tumor metastases, the phenotype of immune 
cells invading the tissues was studied by immunostaining. 
Cells expressing markers of  helper (CD4+), cytotoxic T 
(CD8 +) lymphocytes, or macrophages (Mac-1 +, Mac-2 +, 
Mac-3 +, and the macrophage pitope BMA BM8) were 
rarely if ever observed (not shown). Few cells expressing 
NK cell markers were found in normal tissues (not shown) 
or tumors of  untreated mice (Fig. 3 A), but abundant NK 
cells were localized in B16 subcutaneous tumors of  mice 
treated with hlL-10 (Fig. 3 B) and in subcutaneous tumors 
of  mice injected with IL-10 gene--transfected B16 ceils 
(Fig. 3 C). When double immunostaining was performed 
on the cells expressing the NK cell asialo-GMl antigen 
(Fig. 3 D), these were found to also express the LGL-1 
marker typical of  activated large granular lymphocytes 
(Fig. 3 E). 
Metastasis Inhibition in Various Mouse Models. The involve- 
ment of  NK cells was confirmed by comparing inhibition 
of  tumor metastases in normal C57/BL6 mice, athymic 
ma/nu mice, SCID mice, beige mice, and mice that had 
been depleted of  NK cells (Table 1). While hlL-10 inhib- 
ited most metastases in nu/nu and SCID mice (65.6 and 
64.3% inhibition, respectively), there was little inhibition 
in beige mice or NK cell-depleted mice (14 and 19%, re- 
spectively). These effects were paralleled in experiments 
with IL-10 gene-transfected cells. There was complete me- 
tastasis inhibition in nu/nu and SCID mice when trans- 
fected B16-F10 cells were inoculated into the animals, 
whereas there was only 33% inhibition when the trans- 
fected cells were introduced into beige mice. Thus, with 
both treatments, inhibition was much lower in NK cell- 
deficient mice (beige mice and NK cell-depleted mice) 
than in SCID or nu/nu mice. 
inhibited. Fig. 2 A shows the growth in C57/BL6 mice of  
B16 tumor cells transfected with the hlL-10 gene. No de- 
tectable tumor growth was observed with a clone secreting 
400-500 ng IL-10/48 h/1 million transfected cells, while 
significant growth inhibition was also measured for clones 
expressing lower IL-10 levels (1.4 to 11.8 ng/million cells/ 
48 h). Similarly, hlL-10 secretion by these transfected cells 
inhibited metastasis of  all the B16 clones, with inhibition 
ranging from 85.8 to 100% (Fig. 2 B). Inhibition of  me- 
tastasis was also observed with two hlL-10 gene-transfected 
M27 clones, #G1 (secreting 50 ng/million cells/48 h) and 
#G3 (28 ng/million cells/48 h), for which inhibition on 
Discuss ion  
We used a number of  murine and human tumor cell 
lines to study the effects of  recombinant human IL-10 (hiL- 
l0) protein and of tumor cells transfected with the IL-10 
gene on tumor metastasis. Experimental lung metastases 
were obtained after intravenous injection ofB16-F10 mu- 
rine melanoma cells in normal mice, athymic nu/nu mace, 
beige mice, and mice depleted of  NK  cells by antibody 
treatment; and spontaneous lung metastases were obtained 
by subcutaneous injection of  M27 Lewis lung carcinoma 
cells in C57/BL6 mice, and Lox human melanoma cells in 
SCID mice. We found that soluble IL-10 is able to inhibit 
metastasis of  both experimental and spontaneous lung 
models at IL-10 concentrations that do not have direct in- 
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Figure 3. Immunostaining of tumors in C57/BL6 mice on day 18 after tumor cell injection. LGL-1-FITC labeling of subcutaneous tumors in (A) in 
untreated control mice and (B) mice treated with 100 Izg/kg hlL-10 daily, starting on day 1. (C) Asialo-GM1-FITC labeling of subcutaneous tmnors of 
IL 10 gene--transfected B16 cells. (D) Double immunostaining with asialo-GMt-FITC and (E) LGL-1-Rbodamine of subcutaneous tumors in luice 
treated with 100 Ixg/kg hlL-10, on day 18. 
Table  1. Inhibition q/Lung Metastases in Various Mouse Models 
Mouse model Tumor 
% Inhibition: % Inhibition 
100 b~g/kg hlL-10 gene 
hlL-10 transfection 
nu/nu B16-F10 65.6 %* 100% 
(P = 0.0019) 
scid LOX 80.5%r ND 
(P = 0.002) 
scld B 16-F 10 64.3%* 100% 
(P-- 0.004) 
beige B16-FI0 14%* 33% 
NK cell-depleted B16-F10 19%~ ND 
Tumor cells were transfected with the hlL-10 gene as described in the 
legend to Fig. 2, and B16-F10 clone #1A was used for the studies on 
inhibition with IL-10-gene transfected cells. 
*Mice were inoculated with 5 • 10 4 cells/animal. Treatment was be- 
gun on day 0. The mean number of lung metastases was counted on 
day 9. 
*Mice were inoculated subcutaneously with 5 • 105 cells into the flank 
on day 0. Treatment was carried out on day 1 through day 22. The 
mean number of lung metastases was counted on day 22. 
~Mice were depleted of NK cells with an anti-NKl.l mAb, as de- 
scribed m Materials and Methods. In isotype control experiments with 
lgG2a antibodies, the same treatment with hlL-10 resulted in a 64% in- 
hibition of tumor metastasis. 
hibitory or stimulatory effects on the tumors in vitro or in 
vivo. 
Immunohistological  characterization led to the identifi- 
cation o f  mostly NK  cells at the metastasis sites. These his- 
tological observations were conf irmed by tumor metastasis 
measurements in different mouse models, which showed 
that there is good metastasis inhibit ion due to IL-10 in nor-  
mal mice, athymic nu /nu  mice (lacking T cells), and SCID 
mice (deficient in both B and T cells), but not in beige 
mice (displaying a functional deficiency o f  NK  cells and 
macrophages) or mice specifically depleted o f  NK  cells. 
Thus, whi le macrophages, CD4 + and CD8 + T cells, and 
NK cells have been observed in previous studies to have 
antitumoral effects in different situations, the preponderant 
role o f  NK  cells in el iminating metastases m IL-10-treated 
mice is consistent with findings that IL-10 reduces CD4 + 
antigen-specific proliferation by downregulat ing MHC 
class II expression (10), and that it inhibits macrophage 
activation, cytokine and nitrogen oxide production, expres- 
sion o f  B7, mycobacteriostatic a tivity, and tumor cytotox-  
icity (12-!4,  25-28). Likewise, in primary mixed lym- 
phocyte cultures, IL-10 inhibits allogeneic proliferative and 
cytotoxic responses of  CD4 + and CD8 + T cells (29), and 
preincubation with IL-10 before exposure to tumor-associ- 
ated antigens ignificantly inhibits delayed-type hyper- 
sensitivity responses (30). In contrast, 1L-10 in combinat ion 
with IL-2 increases IL-2- induced NK cell proliferation, and 
582 Inhibition of Tumor Metastasis by IL-I0 
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IL-10 alone induces NK cytotoxicity against NK-resistant 
tumor cells in vitro (31). Furthermore, consistent with our 
results on the inhibition of  tumor metastasis n vivo, IL-10 
has been reported to render mouse lymphoma cells resistant 
to CTL and sensitive to NK-mediated tysis in vitro (32). 
Nonetheless, the observation that both 100 btg/kg hlL-10 
and cells transfected with the hlL-10 gene caused measur- 
able inhibition in beige mice (14 and 33%, respectively) 
suggests that, although NK cells may be the predominant 
effector mechanism responsible for inhibition, IL-10 may 
also partially inhibit metastases through other means, such 
as through its ability to downregulate the production of  
pro-inflammatory cytokines and chemokines (12), which 
enhance the expression of  tumor cell adhesion molecules 
and tumor cell migration (33, 34). In addition, it has re- 
cently been reported that transfected adenocarcinoma cells 
secreting high quantities of  IL-10 (1,500--2,000 ng/million 
cells/48 h) are rejected by a combination of  CD8 + T lym- 
phocytes, NK cells and neutrophils (20), which would also 
be consistent with our observation that our high IL-10 
producing B16-F10 clone (secreting 400-500 ng/million 
cells/48 h) is rejected at the primary tumor stage in normal, 
nu/nu and SCID mice, and that there is still 33% inhibition 
of tumor metastasis n beige mice. 
The IL-10-mediated activation/recruitment of  NK cells 
observed in tumor metastases i  in distinct contrast o the 
inhibition of  NK cytokine production by monocytes/mac- 
rophages (15). While the mechanism used to activate and/ 
or recruit NK cells to sites of  metastasis n vivo remains to 
be elucidated, it has recently been reported that IL-10 in- 
hibits the synthesis of  transforming rowth factor (TGF)-[~ 
(35), which is known to suppress activation of  NK cells 
(36, 37), and that NK cells express the IL-10 receptor (31). 
Given the many pleiotropic activities of  IL-10, many of 
which may indirectly affect NK cell function, it will be in- 
teresting to identify the multiple pathways by which IL-10 
may inhibit tumor metastasis. 
The IL-10 protein appears to have its greatest effect on 
tumor metastasis, although we can not rule out at the mo-  
ment the possibility that the marginal effects on primary tu- 
mor growth may be due to an inability of  IL-10 injected 
intravenously to reach the tumor core, since one of our tu- 
mor cell clones transfected with the IL-10 gene (clone 
#1A) failed to establish primary tumors. Work in our labo- 
ratories is in progress to determine if a synergism, acting on 
both primary and metastasizing tumors, may exist between 
IL-10 and other cytokines, such as IL-2 and IL-4, which 
have previously been reported to inhibit primary tumor 
growth (1, 2, 7, 21). Cancer treatment with IL-10 to in- 
hibit metastases, combined with other cytokines or surgical 
intervention to remove primary tumors, may thus provide 
an effective means of thwarting the spread of many tumors. 
The authors are grateful to Robert Ramos for FACS | analysis; and to Drs. David Whyte, Chuan-Chu 
Chou, and Jimmy Tan (Schering-Plough) and Alice Dautry-Varsat (Institut Pasteur) for critical reading of 
our manuscript and helpful discussions. 
Address correspondence to Dr. Li Mou Zheng at his current address: Vion Pharmaceuticals, Four Science 
Park, New Haven, CT 06511. 
Received for pubtication 23 February 1996 and in revised form 30 May I996. 
References 
1. Fearon, E.R., D.M. Pardoll, T. Itaya, P. Golumbek, H.I. 
Levitsky, J.W. Simons, H. Karasuyama, B. Vogelstein, andP. 
Frost. 1990. Interleukin-2 production by tumor cells bypasses 
T helper function in the generation of an antitumor response. 
Cell. 60:397-403. 
2. Tepper, R.I., P.K. Pattengale, and P. Leder. 1989. Murine 
interleukin-4 displays potent anti-tumor activity in vivo. Cell. 
57:503-512. 
3. Blankenstein, T., Z. Qin, K. Uberla, W. Miiller, H. Rosen, 
H.-D. Volk, and T. Diamanstein. 1991. Tumor suppression 
after tumor cell-targeted tumor necrosis factor ci gene trans- 
fer.J. Exp. Meal. 173:t047-1052. 
4. Blankenstein, T., D.A. Rowley, and H. Schreiber. 1991. Cy- 
tokines and cancer: experimental systems. Curr. Opin. Immu- 
nol. 3:694-698. 
5. Weber, J.S., G. Jay, K. Tanaka, and S.A. Rosenberg. 1987. 
Immunotherapy of a murine tumor with interleukin 2. J. 
Exp. Med. 166:1716-1733. 
583 Zheng et al. 
6. Silagi, S., R. Dutkowski, and A. Schaefer. 1988. Eradication 
of mouse melanoma by combined treatment with recombi- 
nant human interleukin 2 and recombinant murine inter- 
feron-gamma. Int. J, Cancer 41:315-322. 
7. Roth, C., L.M. Mir, M. Cressent, F. Quintin-Colonna, V. 
Ley, D. Fradelizi, and P. Kourilsky. 1992. Inhibition of tu- 
mor growth by histoincompatible c lls expressing interleu- 
kin-2. Int. lmmunol. 4:1429-1436. 
8. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Lev- 
itsky, K. Brose, V. Jackson, H. Hamada, D. PardoU, and 
R.C. Mulligan. 1993. Vaccination with irradiated tumor cells 
engineered to secrete murine GM-CSF stimulates potent, 
specific, and long-lasting anti-tumor immunity. Pro& Natl. 
Acad. Sci. USA. 90:3539-3543. 
9. Yamada, G., Y. Kitamura, H. Sonoda, H. Harada, S. Taki, 
R.C. Mulligan, and H. Osawa. 1987. Retroviral expression 
of the human IL-2 gene in arnurine T cell line results in cell 
growth autonomy and tumorigenicity. EMBO (Eur. Mol. 
o
n
 April 17, 2017
D
ow
nloaded from
 
Published August 1, 1996
Biol. Organ.) J. 6:2705-2709. 
10. de Waal Male@t, R., J. Haanen, H. Spits, M.G. Roncarolo, 
A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, 
andJ.E, de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 
strongly reduce antigen-specific human T cell proliferation 
by diminishing the antigen-presenting capacit T ofmonocytes 
via downregulation f class 1I major histocompatibility com- 
plex expression.J. Exp. Med. 174:915-924. 
11. Go, N.F., B.E. Castle, R. Barret, R. Kastelein, W. Dang, 
T.R. Mosmann, K.W. Moore, and M. Howard. 1990. Inter- 
leukin 10 (IL-10), a novel B cell stimulator,/ factor: unre- 
sponsiveness of X chromosome-linked immunodeficiency B 
cells.J. Exp. Med. 172:1625-1631. 
12. Moore, K.W., A. O'Garra, R. de Waal Male@t, P. Vieira, 
and T.R. Mosmann. 1993. Interleukin-10. Annu. Rev. Immu- 
nol. 11:165-190. 
13. de Waal Male@t, R., J. Abrams, B. Bennett, C.G. Figdor, 
and J.E. de Vries. 1991. Interleukin 10(IL-10) inhibits cyto- 
kine synthesis by human monocytes: an autoregulatory role 
oflL-10 produced by monocytes.J. Exp. Med. 174:1209-1220. 
14. Bogdan, C., Y. Vodovotz, and C. Nathan. 1991. Macrophage 
deactivation by interleukin 10.J. Exp. Med. 174:1549-1555. 
15. Tripp, C.S., S.F. Wolf, and E.R. Unanue. 1993. Interleukin 
12 and tumor necrosis factor alpha are costimulators of inter- 
feron gamma production by natural killer cells in severe com- 
bined immunodeficiency mice with listeriosis, and interleu- 
kin 10 is a physiologic antagonist. Pro& Natl. Acad. Sci. USA. 
90:3725-3729. 
16. Silva, J.S., PJ. Morrissey, K.H. Grabstein, K.M. Mohler, D. 
Anderson, and S.G. Reed. 1992. Interleukin-10 and inter- 
feron-y regulation of Trypanosoma cruzi infection..l. Exp. 
Med. 175:169-174. 
17. Bermudez, L.F., andJ. Champsi. 1993. Infection with Myco- 
bacterium avium induces production ofinterleukin-10 (IL-10), 
and administration of anti-IL-10 antibody is associated with 
enhanced resistance to infection in mice. Infect. Immun. 61: 
3093-3097. 
18. Zheng, L.M., D.M. Ojcius, andJ.D.-E. Young. 1993. Distri- 
bution of perforin-containing cells in normal and pregnant 
mice. Eur.J. Immunol. 23:2085-2091. 
19. Richter, G., S. Kruger Krasagakes, G. Hein, C. Huls, E. 
Schmitt, T. Diamantstein, and T. Blankenstein. 1993. Inter- 
leukin 10 transfected into Chinese hamster ovary cells pre- 
vents tumor growth and macrophage infiltration. Cancer Res. 
53:4134-4137. 
20. Giovarelli, M., P. Musiani, A. Modesti, P. Dellabona, G. Ca- 
sorati, A. Allione, M. Consalvo, F. Cavallo, F. di Pierro, C. 
De Giovanni et al., 1995. Local release of IL-10 by trans- 
fected mouse mammary adenocarcinoma cells does not sup- 
press but enhances antitumor reaction and elicits a strong cy- 
totoxic lymphocyte and antibody-dependent immune 
memory.2 r. lmmunol, 155:3112-3123. 
21. Hock, H., M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamant- 
stein, and T. Blankenstein. 1993. Mechanisms of rejection in- 
duced by tumor cell-targeted gene transfer of interleukin 2, 
interleukin 4, interleukin 7, tumor necrosis factor, or inter- 
feron y. Proc, Natl. Acad. Sci. USA. 90:2774-2778. 
22. Hock, H., M. Dorsch, T. Diamantstein, and T. Blankenstein. 
1991. lnterleukin 7 induces CD4 + T cell-dependent tumor 
rejection.J. Exp. Med. 174:1291-1298. 
23. Kharkevitch, D.D., D. Seito, G.C. Balch, T. Maeda, C.M. 
Balch, and K. ltoh. 1994. Characterization f autologous tu- 
mor-specific T-helper 2 cells in tumor-infiltrating lympho- 
cytes from a patient with metastatic melanoma. Ira. J. Cancer 
58:317-323. 
24. Moormeier, J.A., and H.M. Golomb. 1991. Interferons: clin- 
ical applications. Hairy cell leukemia. In Biologic therapy of 
cancer. V. DeVita, S. Hellman and S. Rosenberg, editor. 
Lippincott, Philadelphia. 275-288. 
25. Nabioullin, R., S. Sone, K. Mizuno, S. Yano, Y. Nishioka, 
T. Haku, and T. Ogura. 1994. Interleukin-10 is a potent in- 
hibitor of tumor cytotoxicity by human monocytes and alve- 
olar macrophages.J. Leukoc. Biol. 55:437-442. 
26. Alleva, D.G., and K.D. Elgert. 1995. Promotion of macro- 
phage-stimulated autoreactive T cell proliferation by inter- 
leukin-10: counteraction of macrophage suppressor activity 
during tumor growth, lmmunobiol. 192:155-171. 
27. Ding, L., P.S. Linsley, L.-Y. Huang, R.N. Germain, and 
E.M. Shevach. 1993. IL-10 inhibits macrophage costimula- 
tory activity by selectively inhibiting the up-regulation of B7 
expression.J. Immunol. 151:1224-1234. 
28. Denis, M., and E. Ghadirian. 1993. IL-10 neutralization aug- 
ments mouse r sistance to systemic Mycobacterium avium nfec- 
tions.J. Imrnunol. 151:5425-5430. 
29. Bejarano, M.T., R. de Waal Male@t, J.S. Abrams, M. Bigler, 
R. Bacchetta, J.E. de Vries, and M.G. Roncarolo. 1992. ln- 
terleukin 10 inhibits allogeneic proliferative and cytotoxic T
cell responses generated in primary mixed lymphocyte cul- 
tures. Int. Immunol. 4:1389-1397. 
30. Beissert, S., J. Hosoi, S. Grabbe, A. Asahina, and R.D. Gran- 
stein. 1995. IL-10 inhibits tumor antigen presentation by epi- 
dermal antigen-presenting cells. J. Immu,ol. 154:1280-1286. 
31. Carson, G.E., MJ. Lindemann, R. Baiocchi, M. Linett, J.C. 
Tan, C.-C. Chou, S. Narula, and M.A. Caligiuri. 1995. The 
functional characterization ofinterleukin-10 receptor expres- 
sion on human atural killer cells. Blood. 85:3577-3585. 
32. Salazar-Onfray, F., M. Petersson, L. Franksson, M. Matsuda, 
T. Blankenstein, K K~irre, and R. Kiessling. 1995. IL-10 
converts mouse lymphoma cells to a CTL-resistant, NK-sen- 
sitive phenotype with low but peptide-inducible MHC class 1 
expression.J. Immunol. 154:6291-6298. 
33. Rice, G.E., and M.P. Bevilacqua. 1989. An inducible ndo- 
thelial cell surface glycoprotein mediates melanoma dhesion. 
Science (Wash. D C). 246:1303-1306. 
34. Burrows, F.J., D.O. Haskard, I.R. Hart, J.F. Marshall, S. Sel- 
kirk, S. Poole, and P.E. Thorpe. 1991. Influence of tumor- 
derived interleukin 1 on melanoma-endothelial cell interac- 
tions in vitro. Cancer Res. 51:4768-4775. 
35. Van Vlasselaer, P., B. Borremans, U. van Gorp, J.R. Dasch, 
and R. De Waal-Malefyt. 1994. Interleukin 10 inhibits trans- 
forming growth factor-~ (TGF-]3) synthesis required for os- 
teogenic ommitment of mouse bone marrow cells..]. Cell 
Biol. 124:569-577. 
36. Moses, H.L., E.Y. Yang, and J.A. Pietenpol. 1990. TGFq3 
stimulation and inhibition of cell proliferation: new mecha- 
nistic insights. Cell. 63:245-247. 
37. Sulitzeanu, D. 1993. Immunosuppressive factors in human 
cancer. Adv. Cancer Res. 60:247-267. 
584 Inhibition of Tumor Metastasis by IL-10 
o
n
 April 17, 2017
D
ow
nloaded from
 
Published August 1, 1996
